Melanoma of the skin is a common type of cancer that primarily affects younger patients. In Stage III melanoma, which does not involve distant metastases, radical resection is curative in 40–50% of the cases. Adjuvant therapy should be discussed with suitable patients, as it can decrease the chance of, or extend the time to, relapse. Such therapies include mitogen-activated protein kinase (MEK), B-Raf proto-oncogene (BRAF), or serine/threonine kinase inhibitors, and immunotherapies against programmed death 1 (PD-1). These agents have significantly improved relapse-free survival (RFS) rates compared with placebo.
In this issue
Rate this content's potential impact on patient outcomes
Thank you!
Please share some more information on the rating you have given